News|Articles|February 3, 2026
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle
Author(s)CoverMyMeds
Key Takeaways
This CoverMyMeds case study leverages IQVIA data to explore how one pharmaceutical brand navigated mature lifecycle stages in a competitive class, implementing seamless prior auth strategies with CoverMyMeds to help lift claim approval rates 22% points on average and mitigate decreasing access.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook
2
Novartis’ Q4 Recap Shows Signs of Looming Patent Cliff
3
FDA Rejects AstraZeneca’s Application for Subcutaneous Indication of Saphnelo
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5